What blood tests do you need before starting TRT?

Before starting TRT you need a baseline blood panel that does two jobs at once: it confirms that your testosterone is genuinely low, and it screens for the conditions that make therapy risky. The core labs are total and free testosterone drawn on two separate mornings, a complete blood count with hematocrit, a PSA where age-appropriate, and a metabolic and lipid panel, with an estradiol test added when symptoms call for it. This page walks through each test and what it tells a provider. For how the full process fits together, see our guide to how to start TRT online and the overview of how online TRT actually works.

What blood tests do you need before starting TRT?

You need a baseline panel built around one diagnostic marker and several safety markers. The diagnostic anchor is a morning total testosterone, confirmed on two separate days, usually paired with free testosterone. The safety markers are a complete blood count that includes hematocrit and hemoglobin, and a prostate-specific antigen (PSA) test for men in the age range where prostate screening applies; an estradiol test is added when a man has breast symptoms rather than as a universal baseline. Most programs add a metabolic panel, a lipid panel, and often thyroid and prolactin tests, because the same symptoms that suggest low testosterone can come from other conditions entirely. Read together, these results tell a provider whether your levels are actually low, whether a treatable cause is being missed, and whether therapy can be started and monitored safely. No single value decides it.

Why two morning testosterone readings instead of one?

Testosterone is confirmed with at least two separate morning blood draws because a single value is easy to misread. Levels follow a daily rhythm, peaking in the early morning and falling through the day, and they also dip after illness, poor sleep, or acute stress. Both the American Urological Association and the Endocrine Society recommend diagnosing low testosterone only after two unequivocally low morning measurements, not one reading and not symptoms alone (AUA Testosterone Deficiency Guideline; Endocrine Society, JCEM 2018). Drawing before roughly 10 a.m., ideally fasting, keeps the two readings comparable. A program that offers therapy off one low number, or off a symptom questionnaire with no confirmatory draw, is skipping the step that separates real deficiency from a bad morning.

Total and free testosterone: what each number measures

Total testosterone measures every molecule of testosterone in your blood, while free testosterone estimates the small fraction that is unbound and biologically active. The two can disagree, which is why both matter. Much of your total testosterone is bound to sex hormone-binding globulin (SHBG) and albumin; when SHBG is high or low, total testosterone can look normal while the free, usable portion is off, which is why the Endocrine Society advises measuring free testosterone when SHBG is altered or the total sits near the lower limit (Endocrine Society, JCEM 2018). A widely used harmonized reference range for healthy young men is 264 to 916 ng/dL (Travison et al., JCEM 2017), and the AUA describes a total testosterone below 300 ng/dL as a reasonable threshold to support a diagnosis. A provider who sees a borderline total with symptoms will often order free testosterone and SHBG to understand what is actually happening rather than treating a single number in isolation.

Estradiol: when men get an estrogen test

Estradiol is the primary estrogen in men, produced when testosterone is converted through the aromatase enzyme, and men need some of it for bone density and libido, so the goal is a healthy balance, not the lowest possible level (Journal of Clinical Investigation review). Unlike testosterone, hematocrit, and PSA, estradiol is not a universal baseline test. The American Urological Association reserves it for men who present with breast symptoms or gynecomastia rather than measuring it in everyone (AUA Testosterone Deficiency Guideline, Statement 9), and the Endocrine Society’s routine monitoring plan centers on testosterone, hematocrit, and prostate risk rather than estradiol (Endocrine Society, JCEM 2018). Some programs still draw a baseline so that if breast tenderness or fluid retention appears after starting TRT there is a value to compare against, which can also guard against over-correcting, since reflexively crushing estradiol with medication is a common mistake. When estradiol is measured, a sensitive assay is preferred, since standard assays are less reliable at the lower levels typical in men (ADLM, Estradiol Testing in Men).

Complete blood count and hematocrit

A complete blood count establishes your baseline red-blood-cell concentration, which testosterone therapy can push higher over time. Testosterone stimulates red blood cell production, and in some men this raises hematocrit and hemoglobin enough to thicken the blood, a condition the AUA calls polycythemia and the Endocrine Society calls erythrocytosis (AUA Testosterone Deficiency Guideline). Knowing your starting hematocrit lets a provider decide whether therapy is safe to begin and gives a reference point for monitoring. Guideline-based care rechecks the CBC after starting and periodically thereafter, and pauses or adjusts the dose if hematocrit climbs past a safe ceiling, the Endocrine Society flags a hematocrit above 54% as the level to act on (Endocrine Society, JCEM 2018). This is one of the clearest reasons TRT is ongoing, monitored care rather than a one-time prescription: the same therapy that helps symptoms also needs a blood count watched over time. Our page on TRT safety questions explains how hematocrit ties in with blood pressure and sleep apnea once treatment starts.

PSA and a prostate baseline

A PSA test records your baseline prostate-specific antigen before therapy so any later change can be interpreted correctly. Testosterone therapy does not cause prostate cancer on the current evidence (AUA Testosterone Deficiency Guideline, Statement 17), but it can raise PSA modestly, and starting with a baseline lets a provider tell an expected shift from one that needs a urology referral. Both the AUA and the Endocrine Society advise checking PSA and prostate risk before therapy in men in the appropriate age range, and rechecking after starting. Younger men without risk factors may not need it, which is exactly the kind of judgment a live clinical visit is for. If your baseline PSA is elevated, a responsible provider investigates that first rather than starting testosterone on top of an unanswered question.

The supporting panel: thyroid, metabolic markers, and lipids

Beyond the core hormone and safety tests, a thorough baseline usually adds thyroid function, a metabolic panel, lipids, and sometimes prolactin, because fatigue, low libido, and low mood have many possible drivers. A high prolactin can point to a pituitary cause of low testosterone that changes the whole plan: the Endocrine Society advises measuring LH and FSH to separate a testicular from a pituitary cause, and adding prolactin and pituitary evaluation when a secondary cause is suspected (Endocrine Society, JCEM 2018). Thyroid disease, poorly controlled blood sugar, and sleep apnea can each mimic or worsen the symptoms people attribute to low testosterone, whose own symptoms are nonspecific. Checking these up front means therapy is not started on a misdiagnosis, and it gives a fuller picture of cardiometabolic health, since testosterone concentrations are themselves affected by obesity and diabetes (Endocrine Society, JCEM 2018). The supporting panel is not upselling; it is the difference between treating a number and understanding a patient.

How your provider reads the results together

Your provider interprets the whole panel as one picture, not one value in isolation. A confirmed low morning total testosterone, consistent symptoms, a safe baseline hematocrit and PSA, and no untreated cause pointing elsewhere (our page on what causes low testosterone covers how LH helps sort those causes) is the combination that supports starting therapy. That review happens in a live audio-video visit with a licensed provider who can also decline if the picture does not fit, not through a form, and as of 2026 it can be done by telehealth under a temporary federal rule in effect through December 31, 2026. A legitimate program never promises therapy before it sees your labs; the labs are what make the decision responsible.